Abbott expects Exact Sciences acquisition to close on March 23

Abbott (ABT) expects to close the acquisition of Exact Sciences (EXAS) on Monday, March 23. The announcement follows receipt of all regulatory clearances necessary for closing. The transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional people. Together with Exact Sciences, Abbott will accelerate innovation, expand access to life-changing diagnostics, and help more people detect and manage cancer at its earliest, most treatable stages. As previously communicated, this transaction is expected to add approximately $3B of incremental sales in 2026, accelerate Abbott’s 2026 sales growth by approximately 0.5% and dilute 2026 adjusted earnings per share by approximately $0.20.